Dual antiplatelet therapy: optimal timing, management, and duration.

Publié in European Hearth Journal – Cardiovascular Pharmacotherapy, le 23 mars 2015.

En savoir plus en consultant le site.

Auteurs : Pierre SABOURET, Sophie K. RUSHTON-SMITH, Mathieu KERNEIS, Johanne SILVAIN, Jean-Philippe COLLET, Gilles MONTALESCOT

Abstract

Platelet activation and aggregability play a key role in the genesis of arterial thrombus secondary to plaque rupture. For coronary patients, inhibition of platelet function is crucial to decrease the rate of major adverse cardiac events but may expose them to excess bleeding risk. Switching P2Y12 inhibitors is common, yet the clinical consequences are unknown. The aim of this review is to provide an overview of the evidence from randomized, clinical trials and epidemiological studies, with a focus on the optimal duration of dual antiplatelet therapy (DAPT) and appropriate agent and dose selection. The report discusses the latest evidence regarding switching therapies during DAPT, the potential benefits of a personalized strategy, management of the preoperative period, and other clinical perspectives in this complex and rapidly changing field. Ongoing trials will be useful to answer to some important unresolved